ISPOR - HPR95 Inflation Reduction Act: Assessing the Impact for New Drug Development, Launch, Life Cycle Management and Loss of Exclusivity

Full Text

HPR95 Inflation Reduction Act: Assessing the Impact for New Drug Development, Launch, Life Cycle Management and Loss of Exclusivity

Abstract

Authors

S. Briggs C. Francois E. Auger A. Busch

Back to Volume 26, Supplemental Issue 6S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now